Disease Domain | Count |
---|---|
Infectious Diseases | 8 |
Hemic and Lymphatic Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 7 |
Synthetic peptide | 1 |
Target |
Mechanism PBPs inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date29 Aug 2017 |
Mechanism Bacterial DNA gyrase inhibitors [+1] |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date19 Jun 2017 |
Target |
Mechanism Peptidoglycan inhibitors [+1] |
Originator Org. |
Active Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date06 Aug 2014 |
Start Date01 Apr 2024 |
Sponsor / Collaborator Hartford Hospital [+1] |
Start Date15 Jun 2023 |
Sponsor / Collaborator |
Start Date13 Apr 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Delafloxacin meglumine ( Bacterial DNA gyrase x Topoisomerase IV ) | Skin and skin structure infections More | Approved |
Oritavancin Diphosphate ( Peptidoglycan ) | Skin and skin structure infections More | Approved |
Meropenem/Vaborbactam ( PBPs x β-lactamase ) | Pyelonephritis More | Approved |
Minocycline Hydrochloride ( 30S subunit ) | Infectious Diseases More | Approved |
Solithromycin ( 50S subunit ) | Community Acquired Pneumonia More | NDA/BLA |